valoctocogene roxaparvovec基因治疗A型血友病的三年结局
GENEr8-1是一项多中心、开放标签、单臂3期试验,纳入134例接受FVIII预防治疗的成人重型A型血友病男性。治疗相关出血的年化出血率从基线4.8次/年降至预防后0.8次/年(P<.0001),第3年为0.97次/年,年化FVIII使用量分别降低96.8%和94.2%,安全性与前几年一致。
要点
- 治疗相关出血年化出血率从基线4.8次/年降至预防后0.8次/年(P<.0001),第3年为0.97次/年。
- 年化FVIII使用量较基线降低96.8%(预防后)和94.2%(第3年)。
- 第156周平均FVIII活性18.4 IU/dL、中位8.3 IU/dL,第3年丙氨酸氨基转移酶轻度升高最常见(23.7%)。
核心结论
- 止血疗效得以维持,安全性与前几年相比保持不变。
研究设计与样本
- 多中心、开放标签、单臂3期GENEr8-1试验,纳入134例接受FVIII预防治疗的成人重型A型血友病男性。
- 疗效终点包括年化出血率、年化FVIII使用量、FVIII活性(发色底物法;基线缺失值按1 IU/dL、停药后按0 IU/dL填补)和成人血友病特异性生活质量问卷。
- 安全性通过不良事件评估。
主要发现
- 第156周时134例中131例仍在研究中,134例中17例恢复预防治疗。
- 治疗相关出血的平均年化出血率从基线4.8次/年(SD 6.5)降至预防后0.8次/年(SD 2.3;P<.0001),第3年为0.97次/年(SD 3.48)。
- 年化FVIII使用量在预防后较基线降低96.8%,第3年降低94.2%。
- 第156周平均和中位FVIII活性分别为18.4 IU/dL(SD 30.8)和8.3 IU/dL;第2至第3年间的FVIII活性下降低于第1至第2年间。
- 第3年末成人血友病特异性生活质量问卷总分较基线平均变化6.6(95%CI 4.24-8.87;P<.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Valoctocogene roxaparvovec transfers a human factor (F)VIII coding sequence into hepatocytes of people with severe hemophilia A to provide bleeding protection. OBJECTIVES: To present 3-year efficacy and safety in the multicenter, open-label, single-arm, phase 3 GENEr8-1 trial. METHODS: GENEr8-1 enrolled 134 adult males with severe hemophilia A who were receiving FVIII prophylaxis. Efficacy endpoints included annualized bleeding rate, annualized FVIII utilization, FVIII activity (chromogenic substrate assay; imputed as 1 IU/dL at baseline and 0 IU/dL after discontinuation), and the Haemophilia-Specific Quality of Life Questionnaire for Adults. Safety was assessed by adverse events (AEs). RESULTS: At week 156, 131 of 134 participants remained in the study; overall, 17 of 134 resumed prophylaxis. Mean annualized bleeding rate for treated bleeds decreased from 4.8 (SD, 6.5) bleeds/y at baseline to 0.8 (SD, 2.3; P < .0001) bleeds/y after prophylaxis (prophylaxis cessation to last follow-up) and 0.97 (SD, 3.48) bleeds/y during year 3. Annualized FVIII utilization decreased 96.8% from baseline after prophylaxis and 94.2% during year 3. At week 156, mean and median FVIII activity were 18.4 (SD, 30.8) and 8.3 IU/dL, respectively. FVIII activity decrease was lower between years 2 and 3 than between years 1 and 2. At the end of year 3, clinically meaningful improvements in the Haemophilia-Specific Quality of Life Questionnaire for Adults Total Score were observed (mean change from baseline, 6.6; 95% CI, 4.24-8.87; P < .0001). Mild alanine aminotransferase elevations remained the most common AE during year 3 (23.7% of participants). A serious AE of B-cell acute lymphoblastic leukemia was considered unrelated to treatment. CONCLUSION: Hemostatic efficacy was maintained, and safety remained unchanged from previous years.
引用
- Madan B, Ozelo MC, Raheja P, et al. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024. PMID: 38614387. doi:10.1016/j.jtha.2024.04.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。